Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7713-20. doi: 10.1158/0008-5472.CAN-09-1013. Epub 2009 Sep 22.

2.

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM.

Hum Gene Ther. 2010 Jan;21(1):51-64. doi: 10.1089/hum.2009.088.

3.

Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):140-9. doi: 10.1038/mt.2010.224. Epub 2010 Oct 26.

4.

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.

Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Gene Ther. 2008 Apr;15(8):604-16. doi: 10.1038/sj.gt.3303098. Epub 2008 Feb 28.

5.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.

6.

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.

Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R.

Gene Ther. 2010 Feb;17(2):158-70. doi: 10.1038/gt.2009.161. Epub 2009 Dec 17.

7.

Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.

Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM, Gao GP, Wilson JM, Barsoum J, Kaiser LR, Albelda SM.

Cancer Res. 2001 Aug 15;61(16):6201-12.

8.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

9.

Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.

Naik S, Nace R, Barber GN, Russell SJ.

Cancer Gene Ther. 2012 Jul;19(7):443-50. doi: 10.1038/cgt.2012.14. Epub 2012 Apr 20.

10.

Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Westcott MM, Liu J, Rajani K, D'Agostino R Jr, Lyles DS, Porosnicu M.

J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.

12.

Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.

Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN.

Gynecol Oncol. 2014 Jan;132(1):194-202. doi: 10.1016/j.ygyno.2013.11.010. Epub 2013 Nov 15.

13.

Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.

Betancourt D, Ramos JC, Barber GN.

J Virol. 2015 Dec;89(23):11786-800. doi: 10.1128/JVI.01356-15. Epub 2015 Sep 16.

15.

Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.

Heiber JF, Barber GN.

J Virol. 2011 Oct;85(20):10440-50. doi: 10.1128/JVI.05408-11. Epub 2011 Aug 3.

16.

VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):150-8. doi: 10.1038/mt.2010.225. Epub 2010 Oct 19.

17.

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.

Blackham AU, Northrup SA, Willingham M, D'Agostino RB Jr, Lyles DS, Stewart JH 4th.

Surgery. 2013 Mar;153(3):333-43. doi: 10.1016/j.surg.2012.09.003. Epub 2012 Oct 25.

18.

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.

Muik A, Dold C, Geiß Y, Volk A, Werbizki M, Dietrich U, von Laer D.

J Mol Med (Berl). 2012 Aug;90(8):959-70. doi: 10.1007/s00109-012-0863-6.

19.

Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.

Wollmann G, Paglino JC, Maloney PR, Ahmadi SA, van den Pol AN.

Virology. 2015 Jan 15;475:1-14. doi: 10.1016/j.virol.2014.10.035. Epub 2014 Nov 21.

20.

Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.

Blackham AU, Northrup SA, Willingham M, Sirintrapun J, Russell GB, Lyles DS, Stewart JH 4th.

J Surg Res. 2014 Apr;187(2):412-26. doi: 10.1016/j.jss.2013.10.032. Epub 2013 Oct 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk